Hap Trading, LLC Lipocine Inc. Call Options Transaction History

Hap Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$0.37 - $8.65 $888 - $20,760	-2,400 Reduced 1.86%	126,700 $0
Q3 2022 Nov 14, 2022	BUY	$0.49 - $7.65 $7,056 - $110,160	14,400 Added 12.55%	129,100 $3,000
Q2 2022 Aug 12, 2022	SELL	$0.73 - $1.34 $8,687 - $15,946	-11,900 Reduced 9.4%	114,700 $6,000
Q1 2022 May 12, 2022	BUY	$0.89 - $1.85 $98,701 - $205,165	110,900 Added 706.37%	126,600 $23,000
Q4 2021 Feb 14, 2022	SELL	$0.99 - $1.2 $10,791 - $13,080	-10,900 Reduced 40.98%	15,700 $0
Q3 2021 Nov 10, 2021	SELL	$1.08 - $1.49 $1,728 - $2,384	-1,600 Reduced 5.67%	26,600 $3,000
Q2 2021 Aug 11, 2021	BUY	$1.17 - $1.59 $3,977 - $5,406	3,400 Added 13.71%	28,200 $5,000
Q1 2021 May 14, 2021	SELL	$1.38 - $2.28 $11,730 - $19,380	-8,500 Reduced 25.53%	24,800 $5,000
Q4 2020 Feb 16, 2021	BUY	$1.2 - $1.69 $12,720 - $17,914	10,600 Added 46.7%	33,300 $4,000
Q3 2020 Nov 13, 2020	BUY	$1.21 - $2.23 $27,467 - $50,621	22,700 New	22,700 $5,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $433M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.